Introduction
============

Warfarin is the most commonly used oral anticoagulant drug in the prevention of thromboembolism. For patients with prosthetic heart valve replacement, the incidence of hemorrhage is inversely connected with the efficacy of anticoagulation and appears to be a major risk indicator for bleeding complications.[@b1-tcrm-13-421],[@b2-tcrm-13-421] It has been reported that the Chinese populations are more sensitive to warfarin than western populations.[@b1-tcrm-13-421],[@b3-tcrm-13-421] To maintain the international normalized ratio (INR) of 2.0--3.0, the mean daily warfarin dosage is lower in Chinese than in Caucasians. This cannot be explained simply by a lower mean body weight among the Chinese.[@b3-tcrm-13-421]

The vitamin K epoxide reductase complex 1 (VKORC1) recycles vitamin K 2, 3-epoxide back to active vitamin K hydroquinone, an important cofactor involved in the activation of vitamin K-dependent clotting factors. VKORC1 is the target enzyme of inhibition of warfarin,[@b4-tcrm-13-421],[@b5-tcrm-13-421] and variants of the *VKORC1* gene are known to be associated with warfarin resistance. Four different exonic mutations have been described in individuals with known warfarin resistance phenotype.[@b6-tcrm-13-421] It was notable that these mutations clustered in the luminal loops of the gene and were predicted to have functional effects.[@b7-tcrm-13-421] More recently, VKORC1 promoter polymorphisms that occur frequently have been discovered. They exhibit linkage disequilibrium, and are associated with higher warfarin dose requirements.[@b8-tcrm-13-421]--[@b10-tcrm-13-421]

Cytochrome P450 2C9 (CYP2C9) is polymorphic in human and is principally responsible for the metabolism of warfarin. Six distinct single-base pair substitution polymorphisms of the CYP2C9 gene have been discovered and are designated \*1 through \*6.[@b11-tcrm-13-421],[@b12-tcrm-13-421] However, known CYP2C9 polymorphisms cannot entirely account for the low-dose requirement of warfarin seen in Chinese patients with mitral valve replacement.

Collectively, genetic polymorphisms are involved in both pharmacodynamic (VKORC1) and pharmacokinetic (CYP2C9) factors. They appear to interplay in the overall inter-individual variability of warfarin doses. In this context, we screened the promoter and the whole exons (exon 1 to 3) of VKORC1 and CYP2C9 exon 4 polymorphisms and investigated their roles in warfarin sensitivity in Chinese population.

Patients and methods
--------------------

A total of 214 patients with warfarin anticoagulant therapy were selected. Average age was 62.1±10.5 years. They were receiving maintenance warfarin therapy with a stable, therapeutic INR between 2 and 2.5 for at least 3 weeks. Mean daily warfarin requirement was from 1.250 to 5.077 mg/day. Standard clinical laboratory tests indicated that all of the patients had normal liver function and renal function. Patients with concurrent medications with potential to affect war-farin's metabolism included amiodarone, non-steroidal anti-inflammatory drugs, cimetidine, thyroid hormone, or carbamazepine were excluded. The study was approved by the Ethics Committee of Tianjin Medical University General Hospital and Shenzhen Sun Yat-sen Cardiovascular Hospital. Written informed consent was obtained from each patient.

Study protocol
--------------

Blood (5--10 mL) was obtained from 12 to 16 h after administration of the last dose of warfarin during a routine clinic visit. The average daily dose of warfarin was calculated from 1-week period, and latest INR was recorded.

Genotyping protocol
-------------------

DNA was extracted with Gentra DNA Isolation Kit (Hilden, Germany). Sequence amplification was performed by polymerase chain reaction. Gene sequencing of VKORC1 promoter and exon 1 to exon 3 and CYP2C9 exon 4 was performed following methodology described previously.[@b8-tcrm-13-421]

Statistical analysis
--------------------

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) for Windows (version 15.0). Continuous data are presented as mean ± standard deviation and analyzed using independent-samples *t*-test, repeated measures analysis of variance (ANOVA), or one-way ANOVA, as appropriate. Categorical variables were expressed as frequencies and analyzed with *χ*^2^ test. Logistic regression was used to analyze the risk factors of outcome. *P*-values \<0.05 were considered statistically significant.

Results
=======

Average body mass index (BMI) of the 214 participants was 24.7±3.8 kg/m^2^. Mean daily warfarin requirement was from 1.250 to 5.077 mg/day when therapeutic INR (2.0--2.5) levels were maintained. Patient demographics are presented in [Table 1](#t1-tcrm-13-421){ref-type="table"}.

Five polymorphisms were identified in this study. They were VKORC1 1173C\>T, 1542G\>C, 2255C\>T, 3730C\>T and CYP2C9 exon 4 −65G\>C. Genotype distributions of all polymorphisms were in Hardy-Weinberg equilibrium. These genotype frequencies are shown in [Table 2](#t2-tcrm-13-421){ref-type="table"}. VKORC1 1173CT, 1542GC, 2255CT and 3730CT carrier status was in the same patients, and CYP2C9 exon 4 −65GC carriers were absolutely different from them. The clinical characteristics of the VKORC1 1173CT, 1542GC, 2255CT, 3730CT carriers, CYP2C9 exon 4 −65GC carriers and the others are exhibited in [Table 3](#t3-tcrm-13-421){ref-type="table"}. These patient groups did not differ significantly in relation to other parameters. However, VKORC1 1173CT, 1542GC, 2255CT, 3730CT carriers and CYP2C9 exon 4 −65GC carriers had significantly higher daily warfarin dosage than the others (3.2±0.6 vs 3.1±1.1 vs 2.6±0.8 mg/day) ([Figure 1](#f1-tcrm-13-421){ref-type="fig"}).

Logistic regression analysis included age, sex, BMI and carrier statuses as covariates and showed that VKORC1 1173CT, 1542GC, 2255CT, 3730CT carriers (odds ratio \[OR\] =3.233, 95% confidence interval \[CI\]: 1.259--8.303, *P*=0.015) and obese individuals (with BMI \>27 kg/m^2^) (OR =1.223, 95% CI: 1.097--1.363, *P*\<0.001) had independent and statistically significant contributions to high warfarin dosage ([Table 4](#t4-tcrm-13-421){ref-type="table"}).

Discussion
==========

Warfarin's anticoagulant activity results from inhibition of hepatic vitamin K epoxide reductase that affects the synthesis of various coagulation factors. Recently, variants of the VKORC1 have been described to have potentially functional consequences.[@b13-tcrm-13-421]--[@b15-tcrm-13-421] However, these polymorphic variants are not useful for testing in Chinese population because of their low prevalence. In the present research, all exons of VKORC1 (exon 1--exon 3) and the promoter were examined by gene sequencing. Four polymorphisms were identified, which were 1173C\>T, 1542G\>C, 2255C\>T, 3730C\>T. The results indicated that polymorphisms are found in absolute linkage disequilibrium since 1173CT, 1542GC, 2255CT, 3730CT are carried by same patients. VKORC1 1173CT could be used as the tagging SNP to represent the others for further research. Logistic analysis showed that 1173CT, 1542GC, 2255CT, 3730CT were one of the independent contributions of high warfarin dosage. This is consistent with previously published report, which indicates that 1173CT was associated with lower VKORC1 mRNA levels in human liver.[@b16-tcrm-13-421] This finding suggests that 1173CT may be associated with the lower levels of reduced form of vitamin K, thereby making patients with this variant more susceptible to the anticoagulation effect of warfarin.

Importantly, VKORC1 1173C\>T genotypes are significantly different among Asians, Caucasians and African Americans. The frequencies of VKORC1 1173C allele in Asians, Caucasians and African Americans were 11%, 58% and 91%, respectively.[@b17-tcrm-13-421]--[@b19-tcrm-13-421] In the present result, the frequency of 1173CT is approximately 14%. Furthermore, multiple regression analysis showed that the VKORC1 1173C\>T variant was an important covariate with respect to the inter-individual variability in warfarin dosage. Patients carrying the C allele at the position of 1173 of the *VKORC1* gene are associated with a significantly higher dose requirement of warfarin. So, these results suggest that the lower dose requirements in Chinese population may possibly reflect the lower frequency of the VKORC1 1173C allele compared to western population.

The other genotypic polymorphism investigated in this research is CYP2C9 exon 4 −65G\>C. Our results revealed that −65C allele appeared to be more significant in patients who were given higher warfarin maintenance dose. Despite the fact that the real function of this novel CYP2C9 polymorphic allele in relation to warfarin metabolism is still unclear, it is possible that the −65C allele affects some important phases in catalytic activity of warfarin that leads to this effect. However, in the multiple regression analysis, presence of CYP2C9 exon 4 −65G\>C did not have any effect on high warfarin dosage when the influence of VKORC1 genotype on the inter-individual variability in warfarin doses was controlled.

BMI \>27 kg/m^2^, which is the Chinese standard for obesity, was the other independent risk factor for high warfarin dosage in the present research. This suggests that obese patients should be considered with higher dose of warfarin to maintain the target INR level. Furthermore, as Chinese population has lower level of BMI than western people,[@b20-tcrm-13-421] the daily requirement of warfarin is also lower. This may be another reason to explain that Chinese population in general is more sensitive to warfarin.

Limitations
===========

Our study has some limitations. Only the CYP2C9 exon 4 DNA sequence was analyzed in the current study. Genetic polymorphism at other loci may be undetected. Further investigation is necessary to investigate the clinical impact of genetic variance of CYP2C9 on warfarin management. In addition, warfarin patients usually visit the clinic every 3--6 months depending on their INR levels. We included only patients into the study if they could return to the clinic for INR testing and warfarin dose follow-up. This led to the relative small sample size of the study.

Conclusion
==========

The warfarin maintenance doses of VKORC1 1173CT, 1542GC, 2255CT and 3730CT carriers and in obese patients were significantly higher than in the others. Our results indicate that the ethnic origin of the warfarin-treated population must be considered as an influencing factor affecting the dose response. In Chinese population, both obesity and the genetic polymorphism of genes affecting the warfarin metabolism seem to affect considerably the clinical response to warfarin.
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###### 

Patient characteristics

  Parameters                    Data
  ----------------------------- ------------
  Sex (M/F)                     111/103
  Age (years)                   58.8±10.9
  BMI (kg/m^2^)                 24.1±3.5
  Smoking (n, %)                73 (34.3%)
  Alcohol drinking (n, %)       29 (13.7%)
  Diabetes mellitus (n, %)      25 (11.8%)
  Kinds of disease              
   Atrial fibrillation (n, %)   74 (34.6%)
   AVR (n, %)                   59 (27.6%)
   MVR (n, %)                   29 (13.6%)
   AVR + MVR (n, %)             27 (12.6%)
   MVR + CABG (n, %)            25 (11.6%)

**Note:** Data are presented as either mean ± SD or counts.

**Abbreviations:** M, male; F, female; BMI, body mass index; AVR, aortic valve replacement; MVR, mitral valve replacement; CABG, coronary artery bypass grafting; SD, standard deviation.

###### 

Genotype distributions

  -------------------------------------------------------------------
  Polymorphisms    Genotype                    Allele   *P*-value
  ---------------- ---------- -------- ------- -------- -------------
  VKORC1\          TT(184)    CT(30)   CC(0)   T(398)   C(30) 0.270
  1173C\>T                                              

  VKORC1\          CC(184)    CG(30)   GG(0)   C(398)   G(30) 0.270
  1542G\>C                                              

  VKORC1\          TT(184)    CT(30)   TT(0)   T(398)   C(30) 0.270
  2255C\>T                                              

  VKORC1\          GG(184)    GA(30)   AA(0)   G(398)   A(30) 0.270
  3730C\>T                                              

  CYP2C9 exon 4\   GG(193)    GC(21)   CC(0)   G(407)   C(21) 0.450
  −65G\>C                                               
  -------------------------------------------------------------------

**Note:** Data in parentheses are numbers of each genotype.

###### 

Clinical characteristics in three groups of genotypes

  Parameters                 VKORC1 1173CT, 1542GC, 2255CT, 3730CT carriers (n=30)   CYP2C9 exon 4 −65GC carriers (n=21)   Others (n=163)   *P*-value
  -------------------------- ------------------------------------------------------- ------------------------------------- ---------------- -----------
  Sex (M/F)                  16/14                                                   7/14                                  88/75            0.344
  Age (years)                56.4±8.1                                                56.2±16.7                             59.5±10.5        0.294
  BMI (kg/m^2^)              24.5±3.1                                                25.2±5.0                              24.0±3.4         0.423
  Smoking (n, %)             10 (33%)                                                5 (25%)                               58 (36%)         0.523
  Alcohol drinking (n, %)    4 (14%)                                                 4 (17%)                               21 (13%)         0.871
  Diabetes mellitus (n, %)   4 (14%)                                                 2 (8%)                                19 (12)          0.512

**Note:** Data are presented as either mean ± SD or counts.

**Abbreviations:** M, male; F, female; BMI, body mass index; SD, standard deviation.

###### 

Logistic regression for patients' covariates that are associated with high warfarin doses

  Covariates                                       OR (95% CI)            *P*-value
  ------------------------------------------------ ---------------------- -----------
  Sex, male                                        1.866 (0.947--3.677)   0.072
  Age                                              1.001 (0.971--1.032)   0.927
  BMI \>27 kg/m^2^                                 1.223 (1.097--1.363)   ,0.001
  VKORC1 1173CT, 1542GC, 2255CT, 3730CT carriers   3.233 (1.259--8.303)   0.015
  CYP2C9 exon 4 −65GC carrier                      2.433 (0.830--7.131)   0.105

**Abbreviations:** OR, odds ratio; CI, confidence interval; BMI, body mass index.
